442 related articles for article (PubMed ID: 28627440)
1. MicroRNA-21 regulates hepatic glucose metabolism by targeting FOXO1.
Luo A; Yan H; Liang J; Du C; Zhao X; Sun L; Chen Y
Gene; 2017 Sep; 627():194-201. PubMed ID: 28627440
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-451 Negatively Regulates Hepatic Glucose Production and Glucose Homeostasis by Targeting Glycerol Kinase-Mediated Gluconeogenesis.
Zhuo S; Yang M; Zhao Y; Chen X; Zhang F; Li N; Yao P; Zhu T; Mei H; Wang S; Li Y; Chen S; Le Y
Diabetes; 2016 Nov; 65(11):3276-3288. PubMed ID: 27495223
[TBL] [Abstract][Full Text] [Related]
3. A decrease in hepatic microRNA-9 expression impairs gluconeogenesis by targeting FOXO1 in obese mice.
Yan C; Chen J; Li M; Xuan W; Su D; You H; Huang Y; Chen N; Liang X
Diabetologia; 2016 Jul; 59(7):1524-1532. PubMed ID: 27003684
[TBL] [Abstract][Full Text] [Related]
4. MiR-542-5p Inhibits Hyperglycemia and Hyperlipoidemia by Targeting FOXO1 in the Liver.
Tian F; Ying HM; Wang YY; Cheng BN; Chen J
Yonsei Med J; 2020 Sep; 61(9):780-788. PubMed ID: 32882762
[TBL] [Abstract][Full Text] [Related]
5. Micro-RNA-27a/b negatively regulates hepatic gluconeogenesis by targeting FOXO1.
Wang S; Ai H; Liu L; Zhang X; Gao F; Zheng L; Yi J; Sun L; Yu C; Zhao H; Li Y
Am J Physiol Endocrinol Metab; 2019 Nov; 317(5):E911-E924. PubMed ID: 31526292
[TBL] [Abstract][Full Text] [Related]
6. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes.
Liu TY; Shi CX; Gao R; Sun HJ; Xiong XQ; Ding L; Chen Q; Li YH; Wang JJ; Kang YM; Zhu GQ
Clin Sci (Lond); 2015 Nov; 129(10):839-50. PubMed ID: 26201094
[TBL] [Abstract][Full Text] [Related]
7. GdCl3 reduces hyperglycaemia through Akt/FoxO1-induced suppression of hepatic gluconeogenesis in Type 2 diabetic mice.
Wang Q; Wang N; Dong M; Chen F; Li Z; Chen Y
Clin Sci (Lond); 2014 Jul; 127(2):91-100. PubMed ID: 24444370
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-185-5p inhibits hepatic gluconeogenesis and reduces fasting blood glucose levels by suppressing G6Pase.
Zheng H; Wan J; Shan Y; Song X; Jin J; Su Q; Chen S; Lu X; Yang J; Li Q; Song Y; Li B
Theranostics; 2021; 11(16):7829-7843. PubMed ID: 34335967
[No Abstract] [Full Text] [Related]
9. lncRNA MEG3 promotes hepatic insulin resistance by serving as a competing endogenous RNA of miR-214 to regulate ATF4 expression.
Zhu X; Li H; Wu Y; Zhou J; Yang G; Wang W
Int J Mol Med; 2019 Jan; 43(1):345-357. PubMed ID: 30431065
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-214 suppresses gluconeogenesis by targeting activating transcriptional factor 4.
Li K; Zhang J; Yu J; Liu B; Guo Y; Deng J; Chen S; Wang C; Guo F
J Biol Chem; 2015 Mar; 290(13):8185-95. PubMed ID: 25657009
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-29a-c decrease fasting blood glucose levels by negatively regulating hepatic gluconeogenesis.
Liang J; Liu C; Qiao A; Cui Y; Zhang H; Cui A; Zhang S; Yang Y; Xiao X; Chen Y; Fang F; Chang Y
J Hepatol; 2013 Mar; 58(3):535-42. PubMed ID: 23111009
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice.
Altomonte J; Richter A; Harbaran S; Suriawinata J; Nakae J; Thung SN; Meseck M; Accili D; Dong H
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E718-28. PubMed ID: 12783775
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin F
Wang Y; Yan S; Xiao B; Zuo S; Zhang Q; Chen G; Yu Y; Chen D; Liu Q; Liu Y; Shen Y; Yu Y
Diabetes; 2018 Sep; 67(9):1748-1760. PubMed ID: 29773555
[TBL] [Abstract][Full Text] [Related]
14. miR‑338‑3p mediates gluconeogenesis via targeting of PP4R1 in hepatocytes.
Wang S; Li L; Chen X; Huang X; Liu J; Sun X; Zhang Y; Shen T; Guo J; Man Y; Tang W; Dou L; Li J
Mol Med Rep; 2018 Oct; 18(4):4129-4137. PubMed ID: 30132533
[TBL] [Abstract][Full Text] [Related]
15. Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice.
Tanaka H; Nagashima T; Shimaya A; Urano Y; Shimokawa T; Shibasaki M
Eur J Pharmacol; 2010 Oct; 645(1-3):185-91. PubMed ID: 20655898
[TBL] [Abstract][Full Text] [Related]
16. Statin suppresses sirtuin 6 through miR-495, increasing FoxO1-dependent hepatic gluconeogenesis.
Shi MY; Bang IH; Han CY; Lee DH; Park BH; Bae EJ
Theranostics; 2020; 10(25):11416-11427. PubMed ID: 33052223
[No Abstract] [Full Text] [Related]
17. Cannabinoid receptor type 1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 activity in a mouse model of obesity.
Chen CC; Lee TY; Kwok CF; Hsu YP; Shih KC; Lin YJ; Ho LT
Int J Mol Med; 2016 Mar; 37(3):743-54. PubMed ID: 26847930
[TBL] [Abstract][Full Text] [Related]
18. Hepatic p38α MAPK controls gluconeogenesis via FOXO1 phosphorylation at S273 during glucagon signalling in mice.
Yang W; Liao W; Li X; Ai W; Pan Q; Shen Z; Jiang W; Guo S
Diabetologia; 2023 Jul; 66(7):1322-1339. PubMed ID: 37202506
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rg1 Inhibits Glucagon-Induced Hepatic Gluconeogenesis through Akt-FoxO1 Interaction.
Liu Q; Zhang FG; Zhang WS; Pan A; Yang YL; Liu JF; Li P; Liu BL; Qi LW
Theranostics; 2017; 7(16):4001-4012. PubMed ID: 29109794
[No Abstract] [Full Text] [Related]
20. TOX3 deficiency mitigates hyperglycemia by suppressing hepatic gluconeogenesis through FoxO1.
Liu C; Zheng Y; Hu S; Liang X; Li Y; Yu Z; Liu Y; Bian Y; Man Y; Zhao S; Liu X; Liu H; Huang T; Ma J; Chen ZJ; Zhao H; Zhang Y
Metabolism; 2024 Mar; 152():155766. PubMed ID: 38145825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
